Ig-like fusion protein for treating membranous nephropathy
Polypeptides targeting fragments of the PLA2R1 receptor with enhanced cytotoxicity are developed to address the limitations of current membranous nephropathy treatments, offering a safer and more effective approach by reducing autoantibodies and autoreactive B cells.
JP2026517900APending Publication Date: 2026-06-02キャノピー イミュノ-セラピューティクス リミテッド
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- キャノピー イミュノ-セラピューティクス リミテッド
- Filing Date
- 2024-05-08
- Publication Date
- 2026-06-02
Smart Images
Figure 2026517900000001_ABST
Abstract
A composition is provided comprising a first polypeptide comprising a first fragment of the extracellular domain of PLA2R1 or an analog or derivative thereof and a dimerization domain, and a second polypeptide comprising a second fragment of the N-terminal extracellular domain of PLA2R1 or an analog or derivative thereof and a dimerization domain. A polypeptide comprising a fragment of the extracellular domain of PLA2R1 is also provided. A pharmaceutical composition comprising the composition, polypeptide, nucleic acid systems and molecules encoding the composition and the polypeptide of the present invention, as well as a therapeutic method using the composition or polypeptide and a method for determining suitability for the treatment, and a method for producing the composition or protein.
Need to check novelty before this filing date? Find Prior Art